Chemistry:SRT2183
From HandWiki
Revision as of 22:21, 30 June 2021 by imported>LinuxGuru (url)
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H24N4O2S |
| Molar mass | 468.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
SRT2183 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to another SIRT1 activator SRT1720, but is closer in potency to resveratrol. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function.[1] However, the claim that SRT2183 is a SIRT1 activator has been questioned[2] and further defended.[3]
See also
References
- ↑ "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes". Nature 450 (7170): 712–6. November 2007. doi:10.1038/nature06261. PMID 18046409. Bibcode: 2007Natur.450..712M.
- ↑ "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1". The Journal of Biological Chemistry 285 (11): 8340–51. March 2010. doi:10.1074/jbc.M109.088682. PMID 20061378.
- ↑ "SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator". The Journal of Biological Chemistry 285 (43): 32695–703. October 2010. doi:10.1074/jbc.M110.133892. PMID 20702418.
 |
